Alnylam Pharmaceuticals Inc (ALNY) — Net Asset Quality Index
Alnylam Pharmaceuticals Inc (ALNY) has a Net Asset Quality Index of 15.9% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $4.97 Billion minus total liabilities of $4.18 Billion yields net assets of $789.18 Million. A higher index indicates a stronger, lower-leverage balance sheet. See Alnylam Pharmaceuticals Inc (ALNY) defensive interval to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Alnylam Pharmaceuticals Inc Net Asset Quality Index Over Time (2002–2025)
This chart shows how Alnylam Pharmaceuticals Inc's Net Asset Quality Index has evolved across 24 annual periods from 2002 to 2025. As of December 2025, the index stands at 15.9%, representing net assets of $789.18 Million against total assets of $4.97 Billion USD. Explore cash flow conversion of Alnylam Pharmaceuticals Inc to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Alnylam Pharmaceuticals Inc (2002–2025)
The table below presents the year-by-year Net Asset Quality Index for Alnylam Pharmaceuticals Inc from 2002 to 2025, covering 24 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market value of Alnylam Pharmaceuticals Inc.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 15.9% | $789.18 Million | $4.97 Billion | $4.18 Billion | ▲ +14.3 pp |
| 2024 | 1.6% | $67.09 Million | $4.24 Billion | $4.17 Billion | ▲ +7.3 pp |
| 2023 | -5.8% | $-220.64 Million | $3.83 Billion | $4.05 Billion | ▼ -1.3 pp |
| 2022 | -4.5% | $-158.22 Million | $3.55 Billion | $3.70 Billion | ▼ -20.6 pp |
| 2021 | 16.1% | $588.20 Million | $3.64 Billion | $3.06 Billion | ▼ -13.7 pp |
| 2020 | 29.8% | $1.02 Billion | $3.41 Billion | $2.39 Billion | ▼ -30.2 pp |
| 2019 | 60.1% | $1.44 Billion | $2.40 Billion | $956.44 Million | ▼ -22.6 pp |
| 2018 | 82.7% | $1.30 Billion | $1.57 Billion | $272.84 Million | ▼ -5.9 pp |
| 2017 | 88.6% | $1.77 Billion | $1.99 Billion | $228.30 Million | ▲ +15.7 pp |
| 2016 | 72.9% | $920.22 Million | $1.26 Billion | $342.59 Million | ▼ -18.3 pp |
| 2015 | 91.2% | $1.26 Billion | $1.39 Billion | $121.80 Million | ▲ +4.5 pp |
| 2014 | 86.7% | $936.27 Million | $1.08 Billion | $143.33 Million | ▲ +22.4 pp |
| 2013 | 64.3% | $270.35 Million | $420.53 Million | $150.18 Million | ▲ +17.7 pp |
| 2012 | 46.6% | $134.05 Million | $287.52 Million | $153.47 Million | ▲ +4.8 pp |
| 2011 | 41.9% | $118.00 Million | $281.92 Million | $163.92 Million | ▲ +1.6 pp |
| 2010 | 40.2% | $158.23 Million | $393.26 Million | $235.03 Million | ▲ +3.3 pp |
| 2009 | 37.0% | $177.97 Million | $481.38 Million | $303.42 Million | ▲ +0.5 pp |
| 2008 | 36.4% | $202.12 Million | $554.68 Million | $352.55 Million | ▼ -3.9 pp |
| 2007 | 40.3% | $199.17 Million | $493.79 Million | $294.62 Million | ▼ -43.5 pp |
| 2006 | 83.8% | $201.17 Million | $240.01 Million | $38.83 Million | ▲ +21.0 pp |
| 2005 | 62.8% | $61.78 Million | $98.35 Million | $36.57 Million | ▼ -7.0 pp |
| 2004 | 69.8% | $46.14 Million | $66.11 Million | $19.96 Million | ▲ +145.7 pp |
| 2003 | -75.9% | $-26.71 Million | $35.18 Million | $61.89 Million | ▼ -47.1 pp |
| 2002 | -28.8% | $-4.65 Million | $16.11 Million | $20.76 Million | — |